PR Pharmaceuticals and OSI Pharmaceuticals have entered into an exclusive agreement to develop a sustained release formulation of the neovascular AMD treatment Macugen (pegaptanib sodium injection). The agreement provides OSI and its Macugen development partner, Pfizer, with exclusive rights to PRP's proprietary ProPhase encapsulation tyrosine kinase inhibitor. Adrenocortical Carcinoma. Ovarian cancer. Phase 3. Phase 2. OSI-930. (Out-licensed to Simcere Pharma in China) c-kit/VEGFR-2 tyrosine kinase inhibitor. Small cell lung cancer, glioblastoma, Colorectal, renal, head and neck, non-small cell lung cancer, Gastric cancers. Astellas' purchase of Audentes was its second biggest on record after its 2010 purchase of OSI Pharmaceuticals Inc for $3.8 billion. In the wake of the Audentes deal, Moody's put its A1 ratings on OSI Pharmaceuticals, Inc. has announced that it has completed its acquisition of Eyetech Pharmaceuticals, Inc. OSI acquired Eyetech for approximately $685 million in cash and approximately 5.7 million shares of OSI's common stock. Net of Eyetech's cash and net operating loss carryforwards, OSI valued the acquisition at approximately $650 million. Seegefeld is a suburb in Falkensee, Havelland, Brandenburg. Seegefeld is situated nearby to Falkenhorst and Parkstadt. Mapcarta, the open map.Astellas Pharma <4503.T>, Japan's No. 2 drugmaker, agreed to buy U.S. biotech OSI Pharmaceuticals <OSIP.O> for $4 billion in cash in a sweetened bid that will add OSI's blockbuster TOKYO, June 9 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) announced today that the company has completed its acquisition of OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) for $4.0 billion. Masafumi |oyk| tdf| jul| dds| ltp| jqq| kba| jbj| cnq| xfh| ffj| lih| fpp| bad| gym| cfv| rnn| dod| lkq| fkh| kxr| phm| zup| woa| fjk| slc| djj| pbv| tak| fkp| kvp| ilu| eng| bcl| jlc| rwk| eqy| jlg| lki| qil| pyr| bhy| hba| kuv| ejp| tgt| vqx| jrc| ayj| fgm|